Non-adherence to osteoporosis therapy places a huge burden on healthcare systems; the cost/patient is six times higher than with diabetes medication.3 Flavour, texture, and pill burden can impact on adherence.4
Accrete is Indicated for the prevention and treatment of vitamin D and calcium deficiency in the elderly. Adjunct to specific osteoporosis treatment for patients at risk of vitamin D and calcium deficiency.5,6
Respecting patient preference is an important way to support treatment persistence.7
With Accrete-D3, patients at risk of calcium and vitamin D3 deficiency have a choice:
Twice-daily, film-coated, swallowable tablets5 | |
OR… | |
Once-daily, orange-flavoured, chewable tablets6 | |
The cost of either treatment option is just £2.95 for 30 days, this is equivalent to approximately £35.89 per year.2,8 | |
Provides savings of up to 37% vs Adcal-D3® Chewable Tablets (56 pack)2,5,6,9-11 |
During pregnancy, daily dose should not exceed 1500 mg calcium and 600 IU vitamin D. See SmPC for more information.
Accrete is the least expensive calcium + vitamin D3 brand offering a choice of swallowable and chewable tablets.1,2
Please complete this form and a member of our team will contact you with specific cost-savings information for your locality.
Please register for an instant download of the Accrete patient guide for more information on the importance of a calcium-vitamin D treatment and tips on how to improve bone health alongside the treatment.
Adcal-D3® is a registered trademark of Kyowa Kirin Services Ltd.
For information on our products please visit EMC, https://www.medicines.org.uk/emc/ and search the product for a Summary of Product Characteristics
Adverse events should be reported to Thornton and Ross Limited by emailing thorntonross@medinformation.co.uk or by calling 01484 848164. Additionally, reporting forms and information can be found at: https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store.
UK-MULT-130a(3) | June 2024
This site is intended to provide information to Healthcare Professionals on Thornton & Ross products.
I am a Healthcare Professional
The information on our Healthcare Professional Website is solely intended for UK Healthcare Professionals and contains promotional information. Click here to return to our main public site.
For information on our products please visit EMC, and search the product for a Summary of Product Characteristics
Adverse events should be reported. Reporting forms and information can be found at: www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Thornton and Ross Limited by emailing thorntonross@medinformation.co.uk or by calling 01484 848164
The website you are going to is maintained by a third party over whom Thornton & Ross Limited has no control or responsibility. We have provided this link as an appropriate resource to our visitors but Thornton & Ross Limited is not responsible for the content or information on this site.
UK-STADA-323 | Date of Preparation November 2023